There are 2137 resources available
1238P - Quality of life with adjuvant gefitinib versus vinorelbine plus cisplatin in patients with completely resected stage II–IIIA (N1–N2) EGFR-mutant non-small cell lung cancer: Results from the ADJUVANT (CTONG1104) study
Presenter: Jian Zeng
Session: E-Poster Display
Resources:
Abstract
1240P - Prognostic impact of the CONtrolling NUTritional status (CONUT) score in patients with stage III non-small cell lung cancer (NSCLC)
Presenter: Vicente Palomar Abril
Session: E-Poster Display
Resources:
Abstract
1241P - Safety monitoring of adjuvant 2 weekly durvalumab for patients with stage III NSCLC: Implications for a 4 weekly regimen during the COVID-19 pandemic and beyond
Presenter: Kroopa Joshi
Session: E-Poster Display
Resources:
Abstract
1242P - Characteristics of the first 615 patients enrolled in Pacific R: A study of the first real-world data on unresectable stage III NSCLC patients treated with durvalumab after chemoradiotherapy
Presenter: Nicolas Girard
Session: E-Poster Display
Resources:
Abstract
1244P - Durvalumab after definitive radiochemotherapy (RCT) in locally advanced unresectable NSCLC: Real-world data on survival and safety from the German expanded access program (EAP)
Presenter: Martin Faehling
Session: E-Poster Display
Resources:
Abstract
1243P - Pathologic response as early endpoint for survival following neoadjuvant therapy (NEO-AT) in resectable non-small cell lung cancer (rNSCLC): Systematic literature review and meta-analysis
Presenter: Nathalie Waser
Session: E-Poster Display
Resources:
Abstract
1245P - The role of surgery for clinical and pathological N2 lung cancer with interstitial pneumonia
Presenter: Kazunori Hata
Session: E-Poster Display
Resources:
Abstract
1246P - Hybrid capture-based assays in primary diagnostics of NSCLC patients: Results from the NEOlung study
Presenter: Balazs Jori
Session: E-Poster Display
Resources:
Abstract
1247P - Uptake of durvalumab in the management of stage III NSCLC: The real-world application of PACIFIC
Presenter: Shelley Kuang
Session: E-Poster Display
Resources:
Abstract
1248P - Immune checkpoint inhibition with chemoradiotherapy (CRT) in stage III non-small cell lung cancer: A systematic review of current evidence and meta-analysis of safety results
Presenter: Adithya Balasubramanian
Session: E-Poster Display
Resources:
Abstract